Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes

Sci Rep. 2021 Oct 13;11(1):20289. doi: 10.1038/s41598-021-96825-3.


Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 patients who had confirmed COVID-19, 31 patients with CD and 124 matched controls were included (median age 72 (64-80) years-old, 44.5% were male). At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p < 0.05). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). In-hospital management, outcomes and complications were similar between the groups. In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Atrial Fibrillation
  • Brazil
  • C-Reactive Protein / analysis
  • COVID-19 / complications*
  • COVID-19 / pathology
  • Chagas Disease / complications
  • Chagas Disease / pathology*
  • Chagas Disease / virology
  • Coinfection
  • Diabetes Mellitus
  • Female
  • Hospital Mortality / trends
  • Hospitalization / statistics & numerical data
  • Hospitalization / trends*
  • Hospitals
  • Humans
  • Hypertension
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2 / pathogenicity


  • C-Reactive Protein